Lexagene Holdings (Lexagene Holdings) Debt-to-Equity : 1.38 (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Debt-to-Equity?

Lexagene Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was $1.20 Mil. Lexagene Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was $0.56 Mil. Lexagene Holdings's Total Stockholders Equity for the quarter that ended in Nov. 2022 was $1.27 Mil. Lexagene Holdings's debt to equity for the quarter that ended in Nov. 2022 was 1.38.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lexagene Holdings's Debt-to-Equity or its related term are showing as below:

LXXGQ's Debt-to-Equity is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

Lexagene Holdings Debt-to-Equity Historical Data

The historical data trend for Lexagene Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Debt-to-Equity Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Debt-to-Equity

Get a 7-Day Free Trial

0.50

0.15

0.20

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Debt-to-Equity	Get a 7-Day Free Trial															0.34	0.20	0.26	0.39	1.38

Competitive Comparison of Lexagene Holdings's Debt-to-Equity

For the Medical Devices subindustry, Lexagene Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexagene Holdings's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lexagene Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lexagene Holdings's Debt-to-Equity falls into.

Lexagene Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lexagene Holdings's Debt to Equity Ratio for the fiscal year that ended in Feb. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.351	+	0.896)	/	6.38
	=	0.20

Lexagene Holdings's Debt to Equity Ratio for the quarter that ended in Nov. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.196	+	0.561)	/	1.273
	=	1.38

Lexagene Holdings (OTCPK:LXXGQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lexagene Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.